BioXcel Therapeutics’ $200 Million Common Stock Offering


Davis Polk advised the underwriters in connection with the offering.

BioXcel Therapeutics, Inc. completed the offering of 4,000,000 shares of its common stock. The common stock is listed on the Nasdaq Capital Market under the symbol “BTAI.”

BofA Securities, Inc., Goldman Sachs & Co. LLC, Jefferies LLC, Guggenheim Securities, LLC, and SunTrust Robinson Humphrey, Inc. acted as underwriters for the offering.

Based in New Haven, Connecticut, BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence-based approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.

The Davis Polk corporate team advising the underwriters included partner Deanna L. Kirkpatrick (Picture), counsel Jeffrey S. Ramsay and associates Jakub P. Jozwiak and Chelsea Renter. Partner David R. Bauer and associates Jay Frankel and Tilak Koilvaram provided intellectual property advice. The tax team included partner Patrick E. Sigmon. The environmental team included counsel David A. Zilberberg. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jakub Jozwiak – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Tilak Koilvaram – Davis Polk & Wardwell; Jeffrey Ramsay – Davis Polk & Wardwell; Chelsea Renter – Davis Polk & Wardwell; Patrick Sigmon – Davis Polk & Wardwell; David Zilberberg – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Bank of America Securities; Goldman Sachs & Co.; Guggenheim Securities; Jefferies; SunTrust Robinson Humphrey, Inc.;

Author: Ambrogio Visconti